行为治疗组合在686项目的临床应用探讨  

作　　者：高海江[1] 刘炳书 陈妍华[1] 王兴生[1] 高海英[1] 强瑞香 张淑艳[1] 孟雪松[1] 赵艳名 

机构地区：[1]秦皇岛市九龙山医院,河北秦皇岛066000

出　　处：《检验医学》2016年第B09期218-219,共2页Laboratory Medicine

摘　　要：目的探讨行为治疗组合在686项目项目的临床应用效果。方法将367例686项目精神分裂症患者以患者住院号码单双号原则随机分为两组，分别给予行为治疗组合加利培酮和单独予以利培酮治疗8周。采用阳性与阴性症状量表（PANSS）、不良反应量表（TESS）评定疗效及不良反应。结果研究组治疗总有效率为86．96％，对照组为62．84％，两组比较差异有统计学意义（〈0．05）。研究组的不良反应稍低于对照组（P〈0．05）。结论行为治疗组合在686项目项目的临床应用效果明显，值得推广。Objective To explore the diagnosis and treatment behavior combination in the clinical application of 686 project. Methods The 367 project 686 schizophrenia patients principle of single and double the number in patients in hospital were randomly divided into two groups, respectively given behavioral therapy combined Gary ketone and separate risperidone treatment for 8 weeks. USES posi rive and negative symptoms scale （PANSS） and adverse reaction scale （TESS） to assess efficacy and adverse reactions. Results Treatment group total effective rate was 86.96 %, control group is 62.84 %, comparing the two groups was statistically significant difference （P〈0.05）. Team＇ s adverse reaction was slightly lower than the control group （P〈0.05）. Conclusion Behavior therapy combination effect of clinical application of project project is in 686, is worth promoting.

关 键 词：行为治疗组合 686项目 精神分裂症 不良行为 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]